98%
921
2 minutes
20
Background: To evaluate the association between the visit-to-visit heart rate variability and the risk of atrial fibrillation (AF) in acute ischemic stroke (AIS).
Methods: We analyzed the data of 8179 patients with AIS. Patients without AF on 12-lead electrocardiography underwent further 24 h Holter monitoring. They were categorized into four subgroups according to the visit-to-visit heart rate variability expressed as the coefficient of variation in heart rate (HR-CV). Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using the HR-CV < 0.08 subgroup as a reference.
Results: The adjusted OR of paroxysmal AF was 1.866 (95% CI = 1.205-2.889) for the HR-CV ≥ 0.08 and <0.10 subgroup, 1.889 (95% CI = 1.174-3.038) for the HR-CV ≥ 0.10 and <0.12 subgroup, and 5.564 (95% CI = 3.847-8.047) for the HR-CV ≥ 0.12 subgroup. The adjusted OR of persistent AF was 2.425 (95% CI = 1.921-3.062) for the HR-CV ≥ 0.08 and <0.10 subgroup, 4.312 (95% CI = 3.415-5.446) for the HR-CV ≥ 0.10 and <0.12 subgroup, and 5.651 (95% CI = 4.586-6.964) for the HR-CV ≥ 0.12 subgroup.
Conclusions: HR-CV can facilitate the identification of patients with AIS at a high risk of paroxysmal AF.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918220 | PMC |
http://dx.doi.org/10.3390/jcm12031050 | DOI Listing |
Am J Respir Crit Care Med
September 2025
Temple University Hospital, Pulm & Crit Care Medicine, Philadelphia, Pennsylvania, United States.
Rationale: AIRFLOW-3 was a 1:1 randomized, double blind, sham controlled trial of the d'Nerva Targeted Lung Denervation (TLD) System in patients with COPD.
Objective: Evaluate the impact of TLD on COPD exacerbations compared to optimal medical treatment.
Methods: AIRFLOW-3 patients were symptomatic (CAT ≥10) with moderate to very severe airflow obstruction (25% ≤ FEV ≤ 80% predicted) and GOLD E status (≥2 moderate or ≥1 severe exacerbation over prior 12 months).
J Neurosurg Anesthesiol
October 2025
Department of Anesthesia and Perioperative Medicine, Western University.
Introduction: Current commercial cerebral oximeters only monitor the frontal lobes, however, some cerebrovascular territories may experience ischemia while others remain well perfused. This pilot study used a novel, high-density, dual-wavelength, time-resolved functional cerebral oximeter (Kernel Flow) with 2000 channels to assess the regional differences of cerebral oxygenation (StO2) in response to hypotension across different vascular territories during shoulder surgery in the beach chair position.
Methods: Twenty-seven adult patients were monitored, recording blood pressure, heart rate, regional cerebral oxygen saturation, and other vital parameters.
ESC Heart Fail
September 2025
Division of Heart Failure and Transplant, Mayo Clinic in Florida, Jacksonville, Florida, USA.
Background: Patients with end-stage heart failure and chronic kidney disease requiring dual-organ transplantation (DOT) face significant challenges in utilizing durable mechanical circulatory support due to the risks associated with renal replacement therapies (RRTs) and multi-organ failure. Given the limited options available for long-term support in this patient population, there remains a critical need for alternative strategies to optimize end-organ function and bridge patients safely to transplant. With prolonged waitlist times for DOT, we present our experience with the Impella 5.
View Article and Find Full Text PDFIEEE Trans Biomed Eng
September 2025
Objetive: This study aims to evaluate the QT adaptation time following gradual heart rate changes estimated from exercise stress test (EST) ECGs as a marker of sudden cardiac death (SCD) risk. The predicted risk value for any cardiovascular death (CVD) is also evaluated.
Methods: Three ECG-derived markers related to QT-RR adaptation time were estimated during the exercise phase of EST, $\check{\tau }_{e}$, during the recovery phase, $\check{\tau }_{r}$, and as the difference between them, $\Delta _{\check{\tau }}$.
JAMA Netw Open
September 2025
Division of Cardiology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei, Taiwan.
Importance: The cardiovascular benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may vary by body mass index (BMI), but evidence on BMI-specific outcomes remains limited.
Objective: To investigate the associations of GLP-1 RA use with cardiovascular and kidney outcomes across BMI categories in patients with type 2 diabetes.
Design, Setting, And Participants: This retrospective cohort study used the Chang Gung Research Database, a clinical dataset covering multiple hospitals in Taiwan.